Literatura académica sobre el tema "Endocannabinois"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Endocannabinois".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Endocannabinois"
Fonseca, B. M., G. Correia-da-Silva, M. Almada, M. A. Costa y N. A. Teixeira. "The Endocannabinoid System in the Postimplantation Period: A Role during Decidualization and Placentation". International Journal of Endocrinology 2013 (2013): 1–11. http://dx.doi.org/10.1155/2013/510540.
Texto completoLee, Yunna, Jeongbin Jo, Hae Young Chung, Charalabos Pothoulakis y Eunok Im. "Endocannabinoids in the gastrointestinal tract". American Journal of Physiology-Gastrointestinal and Liver Physiology 311, n.º 4 (1 de octubre de 2016): G655—G666. http://dx.doi.org/10.1152/ajpgi.00294.2015.
Texto completoSuchopár, Josef, Zdeněk Laštůvka, Simona Mašková, Miroslava Alblová y Antonín Pařízek. "Endocannabinoids". Česká gynekologie 86, n.º 6 (21 de diciembre de 2021): 414–20. http://dx.doi.org/10.48095/cccg2021414.
Texto completoAyakannu, Thangesweran, Anthony H. Taylor, Timothy H. Marczylo, Jonathon M. Willets y Justin C. Konje. "The Endocannabinoid System and Sex Steroid Hormone-Dependent Cancers". International Journal of Endocrinology 2013 (2013): 1–14. http://dx.doi.org/10.1155/2013/259676.
Texto completoKeereetaweep, Jantana y Kent D. Chapman. "Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification". Neural Plasticity 2016 (2016): 1–13. http://dx.doi.org/10.1155/2016/2426398.
Texto completoChan, Hsiu-Wen, Natalie C. McKirdy, Hassendrini N. Peiris, Gregory E. Rice y Murray D. Mitchell. "The role of endocannabinoids in pregnancy". REPRODUCTION 146, n.º 3 (septiembre de 2013): R101—R109. http://dx.doi.org/10.1530/rep-12-0508.
Texto completoFriend, Lindsey, Ryan Williamson, Collin Merrill, Scott Newton, Michael Christensen, Jake Petersen, Bridget Wu, Isaac Ostlund y Jeffrey Edwards. "Hippocampal Stratum Oriens Somatostatin-Positive Cells Undergo CB1-Dependent Long-Term Potentiation and Express Endocannabinoid Biosynthetic Enzymes". Molecules 24, n.º 7 (3 de abril de 2019): 1306. http://dx.doi.org/10.3390/molecules24071306.
Texto completoKano, Masanobu, Takako Ohno-Shosaku, Yuki Hashimotodani, Motokazu Uchigashima y Masahiko Watanabe. "Endocannabinoid-Mediated Control of Synaptic Transmission". Physiological Reviews 89, n.º 1 (enero de 2009): 309–80. http://dx.doi.org/10.1152/physrev.00019.2008.
Texto completoEhrenkranz, Joel y Michael A. Levine. "Bones and Joints: The Effects of Cannabinoids on the Skeleton". Journal of Clinical Endocrinology & Metabolism 104, n.º 10 (8 de agosto de 2019): 4683–94. http://dx.doi.org/10.1210/jc.2019-00665.
Texto completoWang, Yanqing y Brian D. Burrell. "Differences in chloride gradients allow for three distinct types of synaptic modulation by endocannabinoids". Journal of Neurophysiology 116, n.º 2 (1 de agosto de 2016): 619–28. http://dx.doi.org/10.1152/jn.00235.2016.
Texto completoTesis sobre el tema "Endocannabinois"
Serzysko, Malgorzata. "Endocannabinoids and excitotoxicity: lessons from hypoglossal motoneurons". Doctoral thesis, SISSA, 2015. http://hdl.handle.net/20.500.11767/3908.
Texto completoMateu, Codina Gerard Àngel. "Factores genéticos en patología dual". Doctoral thesis, Universitat Autònoma de Barcelona, 2019. http://hdl.handle.net/10803/667189.
Texto completoThe term dual pathology describes the coexistence of one or more mental illnesses and substance use disorders which is very common and is often associated with higher psychiatric severity, and worse medical conditions and social status. Likewise, there is now an important body of research on the important role that the endocannabinoid system (eCB) could play on the neurobiological bases of various neuropsychiatric conditions, such as anxiety, mood disorders or schizophrenia, in addition to several substance use disorders. The purpose of this study is to investigate the association between various polymorphisms of the genes encoding for some endocannabinoid system proteins (cannabinoid receptor 1 [CNR1] and fatty acid amide hydrolase [FAAH]) according to (1) the presence or absence of substance use disorders in the whole sample and (2) according to the presence or absence of dual pathology within the group of subjects diagnosed with a substance use disorder. This is a case-control study with a total sample size of 675 subjects, of whom 362 are controls (C; individuals without any psychiatric diagnosis) and 313 cases (Cs; individuals with a substance use disorder without any co-morbid neuropsychiatric condition [TCS] and those individuals with a substance use disorder with co-morbid neuropsychiatric condition [PD]). A comprehensive comparison including demographics, parental and personal background of psychiatric and substance use disorders (according to DSM-IV-R and performed by using the Spanish validated version of Psychiatric Research Interview for Substance and Mental Disorders (PRISM-IV)) and personality characteristics (evaluated using the Spanish version of the Cloninger’s Temperament and Character Inventory (TCI-R))was performed between both Cs and C groups and between TCS and PD groups. 768 single-nucleotide polymorphisms (SNPs) were genotyped wich were used as genetic markers in an approximation of candidate gene study. Simple statistical analysis of polymorphisms, genes and haplotypes and subsequent multivariate analysis were performed. We will relate the results of genetic analysis with sociodemographic and clinical characteristics. The phenotypical results of the comparison between both Cs and C groups showed that Cs subjects had greater prevalence of family background of mental illness and substance use disorders and a lower score on reward dependence, self-directness, cooperativeness and self-transcendence as regarding on personality traits. Likewise, TCS and PD groups contrast show that PD subjects had higher prevalence of alcohol and cocaine use disorders and lower prevalence of cannabis use disorder, as well as a higher prevalence of family background of mental illness and substance use disorders. In addition, TCS subjects had higher score on harm avoidance and self-transcendence but, interestingly, PD subjects score significantly lower on self-directness. We have found a significant prevalence of the AA/AC variants of SNP rs324420 and TT of SNP rs11576941 (both SNPs belonging to the same haplotype of the FAAH gene) in the Cs group in the association study of CS vs. C. The prevalence was significant in the case of the TT variant of the SNP rs11576941 belonging to the FAAH gene in the TCS group in the association study of TCS vs. C. Furthermore, a subgroup of subjects of the PD group with significantly lower scores in the personality dimension harm avoidance that are characterized by being homozygous GG for the SNP rs806380 of the CNR1 gene have been detected. This allelic variation has been associated with a greater sensitivity for positive stimuli and could represent an endophenotypic marker for those subjects with higher emotional instability and, therefore, with greater clinical potential severity.
Strohm, Daniela. "Modulation der Insulinsignalgebung durch Prostaglandin E2 und Endocannabinoide". Phd thesis, Universität Potsdam, 2010. http://opus.kobv.de/ubp/volltexte/2011/4967/.
Texto completoThe obesity related insulin resistance is accompanied by a low grade inflammation. In response to inflammatory stimuli, PGE2 is released from Kupffer cells and signals through four G-Protein coupled PGE2-receptors (EP1-EP4). Previous work showed that PGE2 attenuated insulin signaling in rat hepatocytes through an EP3ß- and ERK1/2-dependent mechanism. Since EP-receptor expression on hepatocytes varies between species and physiological conditions, the effect of the individual EP receptor subtypes on insulin signaling was studied in hepatoma cell lines expressing individual EP receptor subtypes. HepG2 cells lacking functional EP-receptors, and derivatives stably expressing either EP1 receptor (HepG2-EP1), EP3ß receptor (HepG2-EP3ß) or EP4 receptor (HepG2-EP4) and Fh-hTert cells expressing EP2- and EP4-receptor were pre-incubated with PGE2 for 330 min to mimic the sub-acute inflammation. The cells were subsequently stimulated with insulin for 15 min. Akt and ERK1/2 activation was determined by Western Blotting with phospho-specific antibodies. PGE2 inhibited insulin stimulated Akt phosphorylation in all cell lines expressing EP receptors, except in HepG2 cells which are lacking functional EP receptors. PGE2 increased insulin stimulated phosphorylation of the serine/threonine kinase ERK1/2 in all EP R expressing HepG2 cell lines except in Fh-hTert cells. In HepG2-EP1 and HepG2 EP3ß cells PGE2 increased the serine phosphorylation of the insulin receptor substrate, presumably through an ERK1/2 activation. This IRS-serine phosphorylation leads to attenuation of insulin signal transduction. Inhibiting ERK1/2 activation with a specific inhibitor attenuated the PGE2-dependent inhibition of insulin signal transmission in HepG2 EP3ß cells to some extent. ERK1/2 activation in these cells seems to be of major importance for the observed attenuation of insulin stimulated Akt phosphorylation. Application of inhibitors in the other cell lines stably expressing EP receptors provided evidence that other mechanisms contributed to the attenuation of insulin signaling. Insulin signal transduction in Fh-hTert cells by PGE2 was apparently blocked by an ERK1/2-independent mechanism. Increased PGE2 production during obesity is not limited to the periphery. Signs of inflammation have been detected in the hypothalamus, which might be associated with an increased PGE2 production. Therefore, the EP receptor profile of primary neurons as well as neuronal cell models was characterised in order to investigate, whether PGE2 attenuates insulin signal transduction in neuronal cells similar to what was observed in hepatocytes. Pre-incubation with PGE2 did not attenuate insulin stimulated Akt phosphorylation in all neuronal cells. The EP receptor profile in SH SY5Y cells and in primary neurons varied depending on the differentiation status of the cells. Although Akt-kinase was phosphorylated in response to insulin stimulation in all neuronal cells studied, gene expression of insulin target genes (POMC, AgRP) was not modulated by insulin. This might be due to the low level of differentiation of the investigated cells. In the course of obesity, an over-activation of the endocannabinoid system is detected. Since endocannabinoid receptors are related to EP receptors, it was investigated whether endocannabinoids can interfere with insulin signaling in a similar way as PGE2. Pre-incubation of the neuronal cell line N 41 for 330 min with an endocannabinoid receptor agonist, increased insulin stimulated Akt phosphorylation. This implies an insulin sensitising effect of endocannabinoids. This is contradictory to the endocannabinoid-dependent insulin resistance described in the literature and might be caused by indirect endocannabinoid-triggered mechanisms.
LISAI, SARA. "Nutritional factors influencing tissue omega-3 metabolism and endocannabinoids levels in experimental models and humans". Doctoral thesis, Università degli Studi di Cagliari, 2016. http://hdl.handle.net/11584/266644.
Texto completoPatel, Annie. "Endocannabinoid turnover and function". Thesis, University of Nottingham, 2010. http://eprints.nottingham.ac.uk/12625/.
Texto completoKilaru, Aruna. "Endocannabinoid System in Plants?" Digital Commons @ East Tennessee State University, 2012. https://dc.etsu.edu/etsu-works/4781.
Texto completoNorris, Leonie. "Endocannabinoid modulation of nociceptive processing". Thesis, University of Nottingham, 2010. http://eprints.nottingham.ac.uk/28701/.
Texto completoChilufya, Jedaidah Y., Shivakumar P. Devaiah, Richard R. Sante y Aruna Kilaru. "Endocannabinoid-Like Lipids in Plants". Digital Commons @ East Tennessee State University, 2015. https://dc.etsu.edu/etsu-works/4747.
Texto completoLenz, Frederike. "The endocannabinoid system and autistic behavior in the Fmr1- KO mouse". Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2018. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-231397.
Texto completoBonneville, Marika. "Endocannabinoid Modulation of Post-Ischemia Depression". Thesis, Université d'Ottawa / University of Ottawa, 2016. http://hdl.handle.net/10393/35056.
Texto completoLibros sobre el tema "Endocannabinois"
Pertwee, Roger G., ed. Endocannabinoids. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20825-1.
Texto completoAbood, Mary E., Roger G. Sorensen y Nephi Stella, eds. endoCANNABINOIDS. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-4669-9.
Texto completoMaccarrone, Mauro, ed. Endocannabinoid Signaling. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-2728-0.
Texto completoMaccarrone, Mauro, ed. Endocannabinoid Signaling. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3539-0.
Texto completoMaccarrone, Mauro, ed. New Tools to Interrogate Endocannabinoid Signalling. Cambridge: Royal Society of Chemistry, 2020. http://dx.doi.org/10.1039/9781839160752.
Texto completoKendall, Dave y Stephen Alexander, eds. Behavioral Neurobiology of the Endocannabinoid System. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-88955-7.
Texto completoBehavioral neurobiology of the endocannabinoid system. Berlin: Springer-Verlag, 2009.
Buscar texto completoMelis, Miriam, ed. Endocannabinoids and Lipid Mediators in Brain Functions. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-57371-7.
Texto completoJ, Plutzky, Woods Stephen C y sanofi aventis (Firm), eds. The endocannabinoid system and regulation of energy metabolism. [S.l: sanofi aventis, 2006.
Buscar texto completoS, Onaivi Emmanuel, Sugiura Takayuki y Di Marzo Vincenzo, eds. Endocannabinoids: The brain and body's marijuana and beyond. Boca Raton: Taylor & Francis, 2005.
Buscar texto completoCapítulos de libros sobre el tema "Endocannabinois"
Godlewski, Grzegorz y George Kunos. "Overview of Nonclassical Cannabinoid Receptors". En endoCANNABINOIDS, 3–27. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_1.
Texto completoBurston, James y David Kendall. "Peroxisome Proliferator-Activated Receptors and Inflammation". En endoCANNABINOIDS, 221–33. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_10.
Texto completoMascia, Paola, Gianluigi Tanda, Sevil Yasar, Stephen J. Heishman y Steven R. Goldberg. "Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction". En endoCANNABINOIDS, 235–60. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_11.
Texto completoAbood, Mary E., Roger G. Sorensen y Nephi Stella. "Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors". En endoCANNABINOIDS, 263–80. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_12.
Texto completoKotsikorou, Evangelia y Patricia Reggio. "Overview of Non-CB1/CB2 Cannabinoid Receptors: Chemistry and Modeling". En endoCANNABINOIDS, 29–51. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_2.
Texto completoLu, Hui-Chen, Jane E. Lauckner, John W. Huffman y Ken Mackie. "GPR55 in the CNS". En endoCANNABINOIDS, 55–69. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_3.
Texto completoWhyte, Lauren S. y Ruth A. Ross. "The Role of GPR55 in Bone Biology". En endoCANNABINOIDS, 71–113. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_4.
Texto completoAndradas, Clara, María M. Caffarel, Eduardo Pérez-Gómez, Manuel Guzmán y Cristina Sánchez. "The Role of GPR55 in Cancer". En endoCANNABINOIDS, 115–33. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_5.
Texto completoMcHugh, Douglas y Heather B. Bradshaw. "GPR18 and NAGly Signaling: New Members of the Endocannabinoid Family or Distant Cousins?" En endoCANNABINOIDS, 135–42. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_6.
Texto completoRimmerman, Neta, Ewa Kozela, Rivka Levy, Zvi Vogel y Ana Juknat. "Cannabinoid Signaling Through Non-CB1R/Non-CB2R Targets in Microglia". En endoCANNABINOIDS, 143–71. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4669-9_7.
Texto completoActas de conferencias sobre el tema "Endocannabinois"
"PV-003 - SISTEMA ENDOCANNABINOIDE EN DEPRESIÓN DUAL". En 24 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE PATOLOGÍA DUAL. SEPD, 2022. http://dx.doi.org/10.17579/abstractbooksepd2022.pv003.
Texto completoBilgic, Elif. "Endocannabinoid induced apoptotic cell death on endometriotic cells". En 15th International Congress of Histochemistry and Cytochemistry. Istanbul: LookUs Scientific, 2017. http://dx.doi.org/10.5505/2017ichc.op-12.
Texto completoBouter, Y., M. Brzózka, C. Rohleder, R. Rygula, M. Leweke, J. Wiltfang y U. Havemann-Reinecke. "Effects of social defeat on the endocannabinoid system". En Abstracts of the 30th Symposium of the AGNP. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1606396.
Texto completoGertsch, J. "Endocannabinoid signaling across species – evolution and perspectives for drug discovery". En 67th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) in cooperation with the French Society of Pharmacognosy AFERP. © Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-3399680.
Texto completoAbohalaka, Reshed, Turgut Emrah Bozkurt, Emirhan Nemutlu, Sevgen Celik Onder y Inci Sahin-Erdemli. "The effect of endocannabinoid metabolism inhibition on airway inflammation in mice". En ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3878.
Texto completoCruz, Leonardo Cardoso, Luis Gustavo Fraga Belotto, Sofia Dias Campos Machado y Fabrício de Araújo Moreira. "Possible mechanisms of action of cannabidiol in the epilepsies: a review". En XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.045.
Texto completoOnnis, Valentina, Alessandro Deplano y Monica Demurtas. "Discovery of novel endocannabinoid level modulators by modification of old analgesic drugs". En 4th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2018. http://dx.doi.org/10.3390/ecmc-4-05590.
Texto completoOscoz Irurozqui, Maitane, Maria Guardiola-Ripoll, Carmen Almodóvar-Payà, Salavador Sarró, Amalia Guerrero-Pedraza, Edith Pomarol-Clotet y Mar Fatjó-Vilas. "Cannabis use and genes of endocannabinoid system: their role in psychotic symptoms and cognition in first-episode psychosis." En 22° Congreso de la Sociedad Española de Patología Dual (SEPD) 2020. SEPD, 2020. http://dx.doi.org/10.17579/sepd2020o031.
Texto completoClendenen, S., R. Mcclain y N. Clendenen. "B307 The effect of acetaminophen and total knee arthroplasty on endogenous plasma endocannabinoid levels". En ESRA Abstracts, 39th Annual ESRA Congress, 22–25 June 2022. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/rapm-2022-esra.381.
Texto completoUer, O., C. Weisheit, L. Bindila, M. Velten, H. Treede y G. D. Duerr. "Role of the Endocannabinoid System in Modulation of the Inflammatory Reaction in Aortic Valve Degeneration". En 50th Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1725674.
Texto completoInformes sobre el tema "Endocannabinois"
Sallaberry, Chad y Laurie Astern. The Endocannabinoid System, Our Universal Regulator. Journal of Young Investigators, junio de 2018. http://dx.doi.org/10.22186/jyi.34.5.48-55.
Texto completoGuzmán, Manuel. Endocannabinoides: un nuevo sistema de comunicación en el cerebro. Sociedad Española de Bioquímica y Biología Molecular (SEBBM), noviembre de 2010. http://dx.doi.org/10.18567/sebbmdiv_anc.2010.11.1.
Texto completoGewirtz, David A. The Endocannabinoid System as a Target for Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, agosto de 2010. http://dx.doi.org/10.21236/ada535994.
Texto completoMolina, Patricia E. Endocannabinoids as a Target for the Treatment of Traumatic Brain Injury. Fort Belvoir, VA: Defense Technical Information Center, noviembre de 2012. http://dx.doi.org/10.21236/ada576663.
Texto completoMolina, Patricia E. Endocannabinoids as a Target for the Treatment of Traumatic Brain Injury. Fort Belvoir, VA: Defense Technical Information Center, noviembre de 2013. http://dx.doi.org/10.21236/ada599310.
Texto completoLichtman, Aron. The Endocannabinoid System as a Target for Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, agosto de 2009. http://dx.doi.org/10.21236/ada550908.
Texto completoLichtman, Aron. The Endocannabinoid System as a Target for Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, agosto de 2011. http://dx.doi.org/10.21236/ada558526.
Texto completoKamaruzzaman, Mohd Amir, Muhammad Hibatullah Romli, Razif Abas, Sharmili Vidyadaran, Mohamad Taufik Hidayat Baharuldin, Muhammad Luqman Nasaruddin, Vishnnumukkala Thirupathirao et al. Impact of Endocannabinoid Mediated Glial Cells on Cognitive Function in Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Animal Studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, agosto de 2022. http://dx.doi.org/10.37766/inplasy2022.8.0094.
Texto completoEmery, Sean M., Aron H. Lichtman y David A. Gewirtz. Involvement of the Endocannabinoid System in the Development and Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, febrero de 2013. http://dx.doi.org/10.21236/ada575843.
Texto completoEmery, Sean. Involvement of the Endocannabinoid System in the Development and Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, febrero de 2012. http://dx.doi.org/10.21236/ada560646.
Texto completo